These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 29654555

  • 1. Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.
    Capel M, Mareque M, Álvarez CJ, Lindner L, Oyagüez I.
    Clin Drug Investig; 2018 Jul; 38(7):611-620. PubMed ID: 29654555
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A.
    Int J Chron Obstruct Pulmon Dis; 2018 Jul; 13():3867-3877. PubMed ID: 30568438
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC, Tan EC, Yang MC.
    Int J Chron Obstruct Pulmon Dis; 2018 Jul; 13():1079-1088. PubMed ID: 29670344
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.
    Respir Res; 2018 Nov 20; 19(1):224. PubMed ID: 30458866
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF, Kocks JW, Postma MJ.
    Int J Chron Obstruct Pulmon Dis; 2016 Nov 20; 11():2191-2201. PubMed ID: 27703341
    [Abstract] [Full Text] [Related]

  • 7. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Mölken M, Goosens LM, Buyukkaramikli N, Acciai V.
    Ther Adv Respir Dis; 2016 Oct 20; 10(5):391-401. PubMed ID: 27405723
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
    Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct 20; 10():2055-66. PubMed ID: 26451101
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J.
    Respir Res; 2017 Nov 25; 18(1):196. PubMed ID: 29178871
    [Abstract] [Full Text] [Related]

  • 10. Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD.
    Ramos M, Haughney J, Henry N, Lindner L, Lamotte M.
    Clinicoecon Outcomes Res; 2016 Nov 25; 8():445-56. PubMed ID: 27672337
    [Abstract] [Full Text] [Related]

  • 11. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
    Palli SR, Buikema AR, DuCharme M, Frazer M, Kaila S, Juday T.
    J Comp Eff Res; 2019 Nov 25; 8(15):1299-1316. PubMed ID: 31559852
    [Abstract] [Full Text] [Related]

  • 12. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F, Santus P, Scichilone N, Solidoro P, Contoli M, Braido F, Corsico AG.
    Respir Med; 2017 Apr 25; 125():49-56. PubMed ID: 28340862
    [Abstract] [Full Text] [Related]

  • 13. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr 25; 14():2121-2129. PubMed ID: 31571848
    [Abstract] [Full Text] [Related]

  • 14. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J.
    Lancet; 2016 Sep 03; 388(10048):963-73. PubMed ID: 27598678
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr 03; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 16. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
    Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr 03; 14():447-456. PubMed ID: 30863045
    [Abstract] [Full Text] [Related]

  • 17. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D.
    Lancet; 2017 May 13; 389(10082):1919-1929. PubMed ID: 28385353
    [Abstract] [Full Text] [Related]

  • 18. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA, Cates CJ.
    Cochrane Database Syst Rev; 2015 Oct 22; (10):CD008989. PubMed ID: 26490945
    [Abstract] [Full Text] [Related]

  • 19. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM.
    Value Health; 2005 Oct 22; 8(1):32-46. PubMed ID: 15841892
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C, Pearle J, Kerwin EM, Rose ES, Darken P.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 22; 13():1965-1977. PubMed ID: 29950826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.